AngioDynamics (NASDAQ: ANGO) reported Q3 EPS of $0.19, $0.04 better than the analyst estimate of $0.15. Revenue for the quarter came in at $85.6 million versus the consensus estimate of $88.27 million.

GUIDANCE:

AngioDynamics sees FY2017 EPS of $0.68-$0.70, versus the consensus of $0.67. AngioDynamics sees FY2017 revenue of $352-355 million, versus the consensus of $358.7 million.

The company is revising its FY2017 revenueguidance from a range of $355 million to $360 million to a range of $352 million to $355 million. The company is increasing its FY2017 adjusted EPS guidance from a range of $0.65 to $0.67 to a range of $0.68 to $0.70. The company’s free cash flow guidance remains unchanged at greater than $35 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.